Early changes in bone mass, biochemical bone markers and fibroblast growth factor 23 after renal transplantation

References

• Julian B. A., Laskow D. A., Dubovsky J., Dubovsky E. V., Curtis J. J., Quarles L. D. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544–50
   PubMed Web of Science ®Google Scholar
• Horber F. F., Casez J. P., Steiger U., Czerniak A., Montandon A., Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9: 1–9
   PubMed Web of Science ®Google Scholar
• Kwam J. T. C., Almond M. K., Evans K., Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 1992; 18: 166–8
   PubMedGoogle Scholar
• Grotz W., Mundinger F., Gugel B., Exner V., Kirste G., Schollmeyer P. J. Bone mineral density after kidney transplantation. Transplantation 1995; 59: 982–6
   PubMedGoogle Scholar
• Garnero P., Grimaux M., Demiaux B., Préaudat C., Séguin P., Delmas P. D. Measurement of serum osteocalcin with a human specific two‐site‐radioimmunoassay. J Bone Miner Res 1992; 7: 1389–97
   PubMed Web of Science ®Google Scholar
• Montagnani A., Gonnelli S., Cepollaro C., Mangeri M., Martini S., Franci M. B., et al. A new serum assay to measure N‐terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur J Intern Med 2003; 14: 172–7
   PubMedGoogle Scholar
• Stubbs J., Liu S., Quarles L. D. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302–8
   PubMed Web of Science ®Google Scholar
• Shigematsu T., Kazama J. J., Yamashita T., Fukumoto S., Hosoya T., Gejyo F., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250–6
   PubMed Web of Science ®Google Scholar
• Pande S., Ritter C. S., Rothstein M., Wiesen K., Vassiliadis J., Kumar R., et al. FGF‐23 and sFRP‐4 in chronic kidney disease and post‐renal transplantation. Nephron Physiol 2006; 104: 23–32
   Google Scholar
• Gjesdal C. G., Aanderud S. J., Haga H. J., Brun J. G., Tell G. S. Femoral and whole‐body bone mineral density in middle‐aged and older Norwegian men and women: suitability of the reference values. Osteoporos Int 2004; 15: 525–34
   PubMed Web of Science ®Google Scholar
• Karsdal M. A., Martin T. J., Bollerslev J., Christiansen C., Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res 2007; 22: 487–94
   PubMed Web of Science ®Google Scholar
• Barreto F. C., Barreto D. V., Moyses R. M., Neves C. L., Jorgetti V., Draibe S. A., et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 2006; 69: 1852–7
   PubMed Web of Science ®Google Scholar
• Kulak C. A., Borba V. Z., Kulak Júnior J., Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol 2006; 50: 783–92
   PubMedGoogle Scholar
• Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Heickendorff L., et al. Primary hyperparathyroidism: short‐term changes in bone remodeling and bone mineral density following parthyroidectomy. Bone 1999; 25: 237–44
   PubMedGoogle Scholar
• Christiansen P., Steiniche T., Brixen K., Hessov I., Melsen F., Heickendorff L., et al. Primary hyperparathyroidism: effect on parathyroidectomy on regional bone mineral density in Danish patients: a three‐year follow‐up study. Bone 1999; 25: 589–95
   PubMed Web of Science ®Google Scholar
• Messa P., Sindici C., Cannella G., Miotti V., Risaliti A., Gropuzzo M., et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704–13
   PubMed Web of Science ®Google Scholar
• Lomonte C., Antonelli M., Vernaglione L., Cazzato F., Casucci F., Chimienti D., et al. Are low plasma levels of 25‐(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients?. J Nephrol 2005; 18: 96–101
   PubMedGoogle Scholar
• Garnero P., Hausherr E., Chapuy M. C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 1531–8
   PubMed Web of Science ®Google Scholar
• Ross P. D., Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13: 297–302
   PubMed Web of Science ®Google Scholar
• Evenepoel P., Naesens M., Claes K., Kuypers D., Vanrenterhem Y. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transpl 2007; 7: 1193–200
   PubMed Web of Science ®Google Scholar
• Torres P. U., Friedlander G., de Vernejoul M. C., Silve C., Prié D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008; 73: 102–7
   PubMedGoogle Scholar
• Querings K., Girndt M., Geisel J., Georg T., Tilgen W., Reichrath J. 25‐hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006; 91: 526–9
   PubMed Web of Science ®Google Scholar
• Pascussi J. M., Robert A., Nguyen M., Walrant‐Debray O., Garabedian M., Martin P., et al. Possible involvement of pregnane X receptor‐enhanced CYP24 expression in drug‐induced osteomalacia. J Clin Invest 2005; 115: 177–86
   PubMed Web of Science ®Google Scholar